Statistical model analyzes the cost-effectiveness of semaglutide for non-diabetic obese individuals

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Beacon raises $170M to take on J&J in ocular gene therapy

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 4, 2024

Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent | Psychedelic Finance

VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug

August 3, 2023

Xcovery nabs first FDA approval for lung cancer drug

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.